Q1 Earnings Estimate for TSE:HLS Issued By Stifel Canada

HLS Therapeutics Inc. (TSE:HLS) – Investment analysts at Stifel Canada issued their Q1 2025 EPS estimates for HLS Therapeutics in a research report issued to clients and investors on Tuesday, March 25th. Stifel Canada analyst J. Keywood anticipates that the company will post earnings per share of ($0.16) for the quarter. The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.43) EPS.

Separately, Stifel Nicolaus lifted their price objective on shares of HLS Therapeutics from C$3.50 to C$4.00 and gave the stock a “hold” rating in a report on Wednesday.

HLS Therapeutics Price Performance

HLS stock opened at C$4.66 on Thursday. The firm has a 50 day simple moving average of C$4.19 and a two-hundred day simple moving average of C$3.81. The stock has a market cap of C$103.67 million, a PE ratio of -4.67 and a beta of 1.07. HLS Therapeutics has a one year low of C$3.00 and a one year high of C$5.48. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.